Shui He

2.4k citations

38 papers · 1.7k indexed · 2 hit papers · h-index 13

Impact in

Genetics top 1%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Hematology top 2%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments

Papers in ⓘ

Genetics 15
- Myeloproliferative Neoplasms: Diagnosis and Treatment 11
Hematology 9
- Acute Myeloid Leukemia Research 7

Co-authors: John A. Kellum (1 shared paper)Kyle J. Gunnerson (1 shared paper)Melissa Saul (1 shared paper)Alessandro M. Vannucchi (11 shared papers)Srđan Verstovšek (11 shared papers)Francesco Passamonti (7 shared papers)Jingjin Li (8 shared papers)Mark M. Jones (7 shared papers)
Journals: Blood (15 papers)Journal of Clinical Oncology (3 papers)Critical Care (2 papers)Environmetrics (2 papers)Hematological Oncology (2 papers)
Partner nations: United States Italy United Kingdom

In The Last Decade

Shui He

37 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial 2021 · 264 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 The Lancet Oncology
2015 New England Journal of Medicine

Peers

Countries citing papers authored by Shui He

Since Specialization

Citations

This map shows the geographic impact of Shui He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shui He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shui He more than expected).

Fields of papers citing papers by Shui He

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shui He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shui He. The network helps show where Shui He may publish in the future.

Co-authors

The 25 scholars most cited alongside Shui He, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Shui He Line = papers co-authored together Shui He links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera New England Journal of Medicine ·Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, Claire Harrison, Fabrizio Pane, Pierre Zachée, Ruben A. Mesa, Shui He, Mark M. Jones, William M. Garrett, Jingjin Li, Ulrich Pirron, Dany Habr, Srđan Verstovšek Hit paper breakdown →	2015	594
2	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial The Lancet Oncology ·Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, Kirit M. Ardeshna, Mehdi Hamadani, Brian Hess, Brad S. Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi Zinzani, Karin Havenith, Jay Feingold, Shui He, Yajuan Qin, David Ungar, Xiaoyan Zhang, Carmelo Carlo‐Stella Hit paper breakdown →	2021	264
3	Lactate versus non-lactate metabolic acidosis: a retrospective outcome evaluation of critically ill patients Critical Care ·Kyle J. Gunnerson, Melissa Saul, Shui He, John A. Kellum	2006	257
4	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea Cancer ·Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Peter J. Rosen, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Paola Guglielmelli, Chiara Elena, Shui He, Nancy Contel, Bijoyesh Mookerjee, Victor Sandor, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi	2013	131
5	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Clinical Cancer Research ·Brad S. Kahl, Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella, Paolo F. Caimi, Erin Reid, Jay Feingold, Kirit M. Ardeshna, Melhem Solh, Leonard T. Heffner, David Ungar, Shui He, Joseph Boni, Karin Havenith, Owen A. O’Connor	2019	77
6	Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study The Lancet Haematology ·Mehdi Hamadani, Graham P. Collins, Paolo F. Caimi, Felipe Samaniego, Alexander I. Spira, Andrew Davies, John Radford, Tobias Menne, Anand B. Karnad, Jasmine Zain, Paul Fields, Karin Havenith, Hans G. Cruz, Shui He, Joseph Boni, Jay Feingold, Jens Wuerthner, Steven M. Horwitz	2021	63
7	A comparative study of the use of GAM and GLM in air pollution research Environmetrics ·Shui He, Sati Mazumdar, Vincent C. Arena	2005	42
8	Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma Blood ·Mehdi Hamadani, Graham P. Collins, Felipe Samaniego, Alexander I. Spira, Andrew Davies, John Radford, Paolo Caimi, Tobias Menne, Joseph Boni, Hans G. Cruz, Jay Feingold, Shui He, Jens Wuerthner, Steven M. Horwitz	2018	35
9	A Retrospective Investigation of PM10 in Ambient Air and Cardiopulmonary Hospital Admissions in Allegheny County, Pennsylvania: 1995???2000 Journal of Occupational and Environmental Medicine ·Vincent C. Arena, Sati Mazumdar, Jeanne V. Zborowski, Evelyn O. Talbott, Shui He, Ya–Hsiu Chuang, Joseph J. Schwerha	2006	18
10	Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma Blood ·Graham P. Collins, Steven M. Horwitz, Andrew Davies, Anand B. Karnad, Felipe Samaniego, Alexander I. Spira, Paul Fields, Tobias Menne, Joseph Boni, Hans G. Cruz, Jay Feingold, Shui He, Jens Wuerthner, Mehdi Hamadani	2018	17
11	Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial Journal of Clinical Oncology ·Srđan Verstovšek, Jean‐Jacques Kiladjian, Martin Grießhammer, Tamás Masszi, S. T. S. Durrant, Francesco Passamonti, Claire Harrison, Fabrizio Pane, Pierre Zachée, Ruben A. Mesa, Shui He, Mark M. Jones, William M. Garrett, Jingjin Li, Ulrich Pirron, Tomasz Lawniczek, Alessandro M. Vannucchi	2014	14
12	Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Blood ·Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, Kirit M. Ardeshna, Mehdi Hamadani, Brian Hess, Brad S. Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi Zinzani, Jay Feingold, David Ungar, Yajuan Qin, Shui He, Carmelo Carlo‐Stella	2020	13
13	Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera Blood ·Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Peter J. Rosen, Shui He, Nancy Contel, Bijoyesh Mookerjee, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi	2012	13
14	The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind, Double-Dummy, Symptom Study (RELIEF) Blood ·Ruben A. Mesa, Alessandro M. Vannucchi, Abdulraheem Yacoub, Pierre Zachée, Mamta Garg, Roger M. Lyons, Silwan Chedid, Steffen Koschmieder, Ciro R. Rinaldi, Jenny Byrne, Yasmin Hasan, Francesco Passamonti, Srđan Verstovšek, Deborah Hunter, Mark M. Jones, Shui He, Alex Morozov, Bruno Martino	2014	12
15	Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study Blood ·Paolo F. Caimi, Brad S. Kahl, Mehdi Hamadani, Carmelo Carlo‐Stella, Shui He, David Ungar, Jay Feingold, Kirit M. Ardeshna, John Radford, Melhem Solh, Leonard T. Heffner, Owen A. O’Connor	2018	10
16	Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Blood ·John Radford, Brad S. Kahl, Mehdi Hamadani, Carmelo Carlo‐Stella, Paolo F. Caimi, Kirit M. Ardeshna, Jay Feingold, Shui He, Erin Reid, Melhem Solh, Ki-Young Chung, Leonard T. Heffner, David Ungar, Owen A. O’Connor	2018	9
17	Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia Blood ·Aaron D. Goldberg, Martin S. Tallman, Melhem Solh, David Ungar, David A. Rizzieri, Roland B. Walter, Alexander I. Spira, Ki-Young Chung, Wendy Stock, Shui He, Joseph Boni, Ehab Atallah	2017	8
18	ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT‐301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) Hematological Oncology ·Graham P. Collins, Steven M. Horwitz, Mehdi Hamadani, Felipe Samaniego, Alexander I. Spira, Paolo Caimi, Andrew Davies, Tobias Menne, Paul Fields, Hans G. Cruz, Shui He, Joseph Boni, Jay Feingold, Jens Wuerthner, John Radford	2019	8
19	INTERIM DATA FROM THE FIRST CLINICAL STUDY OF ADCT‐301, A NOVEL PYRROLOBENZODIAZAPINE‐BASED ANTIBODY DRUG CONJUGATE, IN RELAPSED/REFRACTORY HODGKIN/NON‐HODGKIN LYMPHOMA Hematological Oncology ·Steven M. Horwitz, Michelle A. Fanale, A. Spira, Karin Havenith, Shui He, Jay Feingold, Mehdi Hamadani	2017	8
20	Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea Blood ·Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer, Tamás Masszi, Simon Durrant, Pierre Zachée, Fabrizio Pane, Claire Harrison, Shui He, Lance Leopold, Jingjin Li, Ulrich Pirron, Tomasz Lawniczek, Srđan Verstovšek	2013	7

About Shui He

Shui He is a scholar working on Genetics, Hematology, Oncology, Pathology and Forensic Medicine and Health, Toxicology and Mutagenesis, having authored 38 papers that have together received 1.7k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), CAR-T cell therapy research (9 papers), Lymphoma Diagnosis and Treatment (8 papers), Acute Myeloid Leukemia Research (7 papers), Synthesis and pharmacology of benzodiazepine derivatives (6 papers), HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Cytokine Signaling Pathways and Interactions (4 papers). The work is most often cited by research in Genetics (749 citations), Hematology (476 citations), Nephrology (189 citations), Rheumatology (337 citations) and Pathology and Forensic Medicine (372 citations). Shui He has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include John A. Kellum, Kyle J. Gunnerson, Melissa Saul, Alessandro M. Vannucchi, Srđan Verstovšek, Francesco Passamonti, Jingjin Li, Mark M. Jones, Jean‐Jacques Kiladjian and Pierre Zachée. Their work appears in journals such as Blood, Journal of Clinical Oncology, Critical Care, Environmetrics and Hematological Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact